Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orqis Medical Corp.

www.orqis.com

Latest From Orqis Medical Corp.

Where Are They Now? Start-Up Revisits Cardiac Assist Companies

The market for cardiac assist devices has, in the past, been focused on end-stage patients waiting for a heart transplant, a niche market. But now, growth is accelerating in all sectors, from acute cardiac support to the long-term support of end-stage heart failure patients. Start-Up revisits CardiacAssist, CircuLite, and MicroMed.
Business Strategies Platform Technologies

Orqis Gains Momentum with Congestive Heart Failure Device

Orqis Medical slid in under the wire to present late-breaking clinical results for a landmark trial in congestive heart failure at the American College of Cardiology meeting in Chicago in April. Relative to the trial's design, the results were somewhat mixed. The company failed to meet its clinical trial endpoints, but demonstrated significant improvements in a very sick acute heart failure population in a first-of-its kind study, and therefore, proof-of-principle of its novel approach. So, what appears at first glance to be bad news, is actually pretty good news.
Medical Device Clinical Trials

Paracor: Can a Mechanical Device Treat Heart Failure?

Heart failure is a huge growing market in which devices are looking to succeed where drugs have provided only limited benefit. Paracor is taking on the role of David In a field dominated by the Goliaths in cardiac rhythm management and their powered devices. The company is betting that its strategy to focus first on a mechanical approach offers a better alternative for many patients not well-served by current therapies.
Medical Device Clinical Trials

Interventional Heart Failure

Medical device investors who have avoided heart failure, because of the long and uncertain development course of ventricular assist devices, should take another look. The minimally invasive revolution in heart failure, to some extent a logical extension of interventional cardiology's migration into other areas of structural heart disease like heart valves and PFOs, is providing new device opportunities, which have the potential to get to market sooner and at the same address an even larger patient population than heart failure devices that came before.
Medical Device Platform Technologies
See All

Company Information

  • Industry
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Orqis Medical Corp.
  • Senior Management
  • Ken Charhut, Pres. & CEO
    Marvin A Konstam, MD, Medical Dir.
  • Contact Info
  • Orqis Medical Corp.
    Phone: (949) 707-5890
    14 Orchard Rd.
    Ste. 100
    Lake Forest, CA 92630
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register